Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Bruxelles  >  Oxurion    OXUR   BE0003846632

OXURION (OXUR)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Euronext Bruxelles
09/18/2018 09/19/2018 09/20/2018 09/21/2018 09/24/2018 Date
5.7(c) 5.42(c) 5.44(c) 5.71(c) 5.44 Last
218 611 335 132 266 932 169 548 77 886 Volume
-5.16% -4.91% +0.37% +4.96% -4.73% Change
More quotes
Financials (EUR)
Sales 2018 3,00 M
EBIT 2018 -
Net income 2018 -29,0 M
Debt 2018 -
Yield 2018 -
Sales 2019 3,00 M
EBIT 2019 -
Net income 2019 -28,0 M
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 72,8x
Capi. / Sales2019 72,8x
Capitalization 219 M
More Financials
Company
Oxurion NV is a biopharmaceutical company, which engages in developing and commercializing medicines for the treatment of vitreo retinal diseases.It operates under JETREA (ocriplasmin) brand name.The company was founded by Desire Collen in 1991 and is headquartered in Leuven, Belgium. 
More about the company
Latest news on OXURION
08:24aOXURION : enrolls first patient in clinical trial evaluating DME therapy
AQ
09/21OXURION : Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (an..
AQ
09/20OXURION : nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687,..
GL
09/20OXURION : Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (an..
GL
09/18OXURION : to present further scientific findings supporting therapeutic potentia..
AQ
09/17OXURION : to present further scientific findings supporting therapeutic potentia..
PU
09/17OXURION : NV to present further scientific findings supporting therapeutic poten..
GL
09/11OXURION : Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch of..
AQ
09/10OXURION : Announces New Euronext Brussels Stock Ticker “OXUR” and La..
PU
09/10OXURION : NV Announces New NYSE Euronext Brussels Stock Ticker "OXUR" and Launch..
GL
More news
Sector news : Biotechnology & Medical Research - NEC
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Biotechnology & Medical Research - NEC
MarketScreener Strategies on OXURION 
THROMBOGENICS - 2012
The bullish trend continues
BUY
More Strategies
Latest Tweets
09/21Oxurion nv Enrolls First Patient in Phase 1 Clinical Trial Evaluating THR-687.. 
09/20SmartInsider - 2 directors bought: Two Directors at Oxurion NV bought 7,000 s.. 
09/20Oxurion Enrolls First Patient in Phase 2 Clinical Study Evaluating THR-317 (a.. 
09/18Oxurion NV to present further scientific findings supporting therapeutic pote.. 
09/13Oxurion $OXUR new POC study to be launched w/ THR-317 to treat a rare disease.. 
More tweets
Qtime:6
News from SeekingAlpha
09/04ThromboGenics becomes Oxurion 
06/27ThromboGenics plans name change to ?Oxurion? 
05/25ThromboGenics enrolls first patient in Phase 1 clinical study evaluating THR-.. 
04/27ThromboGenics commences mid-stage study of THR-317/Lucentis combo in DME 
04/11FDA OKs AI software to detect diabetic retinopathy 
Chart OXURION
Duration : Period :
Oxurion Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OXURION
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 6,00 €
Spread / Average Target 5,1%
Managers
NameTitle
Patrik de Haes Chief Executive Officer & Executive Director
Thomas Moragne Clay Chairman
Dominique Vanfleteren Chief Financial Officer
Susan Schneider Chief Medical Officer
David R. Guyer Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
OXURION68.79%245
CELLTRION, INC.--.--%33 388
IQVIA HOLDINGS INC30.32%25 763
LONZA GROUP18.80%24 291
INCYTE CORPORATION-29.69%14 156
SEATTLE GENETICS, INC.45.35%12 348